A Phase 2 interventional study of Xcelerated Recovery Nutritional Supplement in Postoperative Recovery and Total Knee Arthroplasty, sponsored by University of California, San Francisco. Not yet recruiting at 1 site in United States. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by University of California, San Francisco · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study tests whether taking an essential amino acid (EAA) dietary supplement, Xcelerated Recovery (XR), around the time of knee replacement surgery changes the normal swelling that happens during recovery. Adults 40 years of age or older with knee osteoarthritis who are having a robotic-assisted total knee replacement at UCSF, and who screen positive for nutritional risk or reduced muscle strength, will be randomly assigned to standard care plus XR or to standard care alone. Swelling will be measured with a tape measure by a team member who does not know which group the participant is in. All participants will also use a temporary skin sensor and smartphone app (InkWell) that measures knee swelling, range of motion, and skin temperature.
This is a single-site, randomized, two-arm interventional study at UCSF evaluating the effect of perioperative supplementation with Xcelerated Recovery (XR), a commercially available EAA-based dietary supplement, on normal physiological recovery after elective primary unilateral robotic-assisted total knee arthroplasty (TKA). The study evaluates normal structure and function during recovery (limb circumference as a marker of tissue fluid balance). It is not intended to evaluate the supplement's ability to diagnose, cure, mitigate, treat, or prevent any disease.
Eighty participants will be randomized 1:1 in REDCap using permuted blocks of 4, after informed consent and confirmation of eligibility. The intervention group takes one full serving of XR dissolved in water (19.2 g EAA per serving) twice daily (38.4 g EAA per day) from 7 days before surgery through 14 days after surgery, in addition to standard care. The control group receives standard care alone.
The primary outcome is change from baseline in standardized mid-patellar and limb circumference, measured with a tape measure at baseline (about 7 days before surgery), 2 weeks, and 1 month after surgery by a trained team member who is blinded to study arm. Both groups use the InkWell remote monitoring platform (a temporary skin-applied sensor and smartphone app), which uses AI enabled software to generate exploratory measurements of knee swelling, range of motion, and skin temperature from about 7 days before surgery through postoperative day 14. Exploratory outcomes also include patient reported pain (VAS) and agreement between InkWell and tape measurements. Supplement adherence, adverse events, postoperative complications, length of stay, and 30-day readmissions are collected for descriptive and safety purposes.
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 19, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to this arm will receive the Xcelerated Recovery (XR) nutritional supplement in addition to standard perioperative care. Participants will dissolve the full XR supplement dissolved in water which includes 19.2 g of essential amino acids twice daily (38.4 g/day), beginning 7 days before total knee arthroplasty and continuing through 14 days after surgery. Participants will also undergo the study's scheduled assessments and exploratory InkWell monitoring.
Drug: Xcelerated Recovery Nutritional Supplement
Participants randomized to this arm will receive standard perioperative care without the Xcelerated Recovery nutritional supplement. Participants will undergo the same scheduled study assessments and exploratory InkWell monitoring as the intervention group.
Xcelerated Recovery (XR) is a commercially available, EAA-based multi-ingredient nutritional supplement. Participants assigned to the intervention arm will dissolve the full XR supplement in water and consume it twice daily. Each serving contains 19.2 g of essential amino acids, providing 38.4 g of essential amino acids per day. Supplementation will begin 7 days before total knee arthroplasty and continue through 14 days after surgery. XR is being evaluated for its association with measures of normal physiological recovery following surgery, including tissue fluid balance assessed through changes in limb circumference.
Change in Mid-Patellar and Limb Circumference From Baseline
Mid-patellar and limb circumference of the operative knee will be measured in centimeters using a standardized measurement technique. Change from the preoperative baseline measurement will be compared between the Xcelerated Recovery nutritional supplement and control groups as a measure of postoperative tissue fluid balance. Measured by a trained team member who is blinded to study arm.
Time frame: Baseline (preoperative), 2 weeks postoperative, and 1 month postoperative
InkWell Sensor Measurement of Postoperative Tissue Fluid Changes
The InkWell Health temporary skin sensor and associated mobile application will generate exploratory measurements related to changes in tissue fluid status. InkWell-derived measurements will be compared with standardized circumference measurements.
Time frame: From 7 days preoperative through 14 days postoperative
InkWell Sensor-Derived Knee Range of Motion
Knee range of motion estimates generated by the InkWell monitoring platform will be collected as an exploratory outcome and compared with standardized range-of-motion measurements.
Time frame: From 7 days preoperative through 14 days postoperative
Skin Temperature Measured Using InkWell Sensor
Skin temperature measurements generated by the InkWell monitoring platform will be collected as an exploratory measure during the perioperative monitoring period.
Time frame: From 7 days preoperative through 14 days postoperative
Xcelerated Recovery Nutritional Supplement Adherence
Participants assigned to the Xcelerated Recovery group will report the number of prescribed supplement doses missed during the supplementation period. Adherence will be summarized based on completed versus prescribed doses.
Time frame: From 7 days before surgery through 14 days after surgery
Postoperative Complications
Postoperative complications documented in the medical record will be collected and compared between study groups.
Time frame: From surgery through 1 month postoperative
All-Cause Hospital Readmission Within 30 Days
The occurrence of hospital readmission following total knee arthroplasty will be determined through review of the medical record and recorded as the number and proportion of participants with at least one readmission.
Time frame: Within 30 days after surgery
Hospital Length of Stay in days following surgery until participant returns home
Length of stay following total knee arthroplasty will be determined from the medical record and recorded as the time from hospital admission to discharge.
Time frame: From surgical admission through hospital discharge, up to 1 month
Change in Pain Score From Baseline using the Visual Analog Scale (VAS)
Participant-reported pain will be assessed using the Visual Analog Scale (VAS) ranging from 1 (no pain) to 10 (worse pain possible). Pain scores will be collected before surgery and at postoperative follow-up visits.
Time frame: Baseline (preoperative), 2 weeks postoperative, and 1 month postoperative
Change in Operative Knee Range of Motion From Baseline
Operative knee flexion and extension will be measured in degrees. Measurements will be obtained using the same standardized approach at each study visit to evaluate change in knee mobility during postoperative recovery.
Time frame: Baseline (preoperative), 2 weeks postoperative, and 1 month postoperative
Plan to share: No
Start is estimated for Jan 2027; primary completion for May 2027, 4 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →